9月29日,专注减重药物的生物技术公司Metsera公布了其超长效GLP-1受体激动剂MET-097i的两项IIb期研究积极结果,这距离辉瑞同意以最高73亿美元收购Metsera仅一周。根据GlobeNewswire和Reuters报道,VESPER-1试验的顶线数据和VESPER-3的初步耐受性结果支持Metsera计划于2025年底启动III期研究。这些试验在无2型糖尿病的重度或肥胖人群中评估...
Source Link9月29日,专注减重药物的生物技术公司Metsera公布了其超长效GLP-1受体激动剂MET-097i的两项IIb期研究积极结果,这距离辉瑞同意以最高73亿美元收购Metsera仅一周。根据GlobeNewswire和Reuters报道,VESPER-1试验的顶线数据和VESPER-3的初步耐受性结果支持Metsera计划于2025年底启动III期研究。这些试验在无2型糖尿病的重度或肥胖人群中评估...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.